Integer (NYSE:ITGR – Get Free Report)‘s stock had its “overweight” rating reissued by investment analysts at Piper Sandler in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $97.00 price objective on the medical equipment provider’s stock, up from their prior price objective of $87.00. Piper Sandler’s target price suggests a potential upside of 15.18% from the company’s current price.
Other research analysts also recently issued reports about the stock. Raymond James Financial reiterated an “outperform” rating and issued a $101.00 price target on shares of Integer in a research report on Monday, February 23rd. Wall Street Zen downgraded shares of Integer from a “buy” rating to a “hold” rating in a research report on Sunday, January 25th. Wells Fargo & Company increased their price target on shares of Integer from $72.00 to $84.00 and gave the stock an “equal weight” rating in a research report on Friday, February 20th. Citigroup increased their price objective on shares of Integer from $75.00 to $92.00 and gave the stock a “neutral” rating in a research note on Friday, February 20th. Finally, Truist Financial increased their price objective on shares of Integer from $95.00 to $97.00 and gave the stock a “buy” rating in a research note on Friday, February 20th. Four research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, Integer has an average rating of “Hold” and an average target price of $98.71.
Check Out Our Latest Report on ITGR
Integer Stock Performance
Integer (NYSE:ITGR – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported $1.20 earnings per share for the quarter, missing analysts’ consensus estimates of $1.21 by ($0.01). The company had revenue of $439.58 million for the quarter, compared to the consensus estimate of $426.48 million. Integer had a net margin of 5.55% and a return on equity of 13.26%. The firm’s revenue for the quarter was up .5% on a year-over-year basis. During the same quarter last year, the company earned $1.31 EPS. Integer has set its FY 2026 guidance at 5.830-6.400 EPS. As a group, research analysts predict that Integer will post 6.47 earnings per share for the current year.
Insider Activity
In other news, VP Tommy P. Thomas sold 825 shares of the firm’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $85.00, for a total value of $70,125.00. Following the completion of the sale, the vice president owned 4,381 shares in the company, valued at approximately $372,385. This trade represents a 15.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.10% of the company’s stock.
Institutional Trading of Integer
A number of large investors have recently made changes to their positions in the stock. Sequoia Financial Advisors LLC bought a new stake in Integer during the 1st quarter valued at about $267,000. ARGA Investment Management LP bought a new position in shares of Integer during the 1st quarter worth approximately $1,209,000. Kestra Advisory Services LLC raised its stake in shares of Integer by 6.2% during the 1st quarter. Kestra Advisory Services LLC now owns 22,755 shares of the medical equipment provider’s stock worth $2,002,000 after acquiring an additional 1,331 shares in the last quarter. Azzad Asset Management Inc. ADV raised its stake in shares of Integer by 2.5% during the 1st quarter. Azzad Asset Management Inc. ADV now owns 15,211 shares of the medical equipment provider’s stock worth $1,339,000 after acquiring an additional 378 shares in the last quarter. Finally, Louisiana State Employees Retirement System bought a new position in shares of Integer during the 1st quarter worth approximately $1,364,000. 99.29% of the stock is owned by hedge funds and other institutional investors.
Key Stories Impacting Integer
Here are the key news stories impacting Integer this week:
- Positive Sentiment: Revenue and organic growth beat expectations — Q1 sales were roughly $440M (up 0.5% year-over-year) with 1.3% organic growth, driven by strength across key product lines. This topline beat is supporting optimism on demand recovery. ITGR Stock Up Despite Q1 Earnings Missing Estimates, Revenues Rise Y/Y
- Neutral Sentiment: Board has initiated a strategic review to “maximize stockholder value” (including possible sale, merger or other combinations). A review can unlock value but also creates execution and process uncertainty; outcomes are binary and timing is unclear. Integer Announces Strategic Review to Maximize Stockholder Value
- Neutral Sentiment: Company published the full Q1 release, slide deck and held its earnings call (transcript and presentation available). These materials provide detail on segment trends and margin drivers for investors doing deeper diligence. Integer Holdings Corporation 2026 Q1 – Results – Earnings Call Presentation
- Neutral Sentiment: Trading was temporarily halted pre-market on the day of the release for “news pending,” which typically increases short-term volume and volatility once resumed. Integer Announces Strategic Review to Maximize Stockholder Value
- Negative Sentiment: EPS missed consensus by a penny — reported $1.20 vs. $1.21 expected — and year-over-year EPS declined from $1.31, reflecting margin pressure that investors are watching closely. Integer (ITGR) Q1 Earnings Lag Estimates
- Negative Sentiment: FY 2026 EPS guidance was set to $5.83–$6.40, below the consensus (~$6.49), which raises investor concern about margin recovery and near-term earnings growth — a key reason for today’s downside pressure. Integer Q1 2026 Press Release / Guidance
About Integer
Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.
Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.
Featured Articles
Receive News & Ratings for Integer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integer and related companies with MarketBeat.com's FREE daily email newsletter.
